Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER studyDavid M. Ross, Timothy P. Hughes, Susan Branford et al.|Blood|2013Cited by 705
TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targetsDavid T Yeung, Timothy P. Hughes, Deborah L. White et al.|Blood|2014Cited by 102
Long-term treatment-free remission of chronic myeloid leukemia with falling levels of residual leukemic cellsTimothy P. Hughes, David M. Ross, Ilaria S. Pagani et al.|Leukemia|2018Cited by 78
Combination of Nilotinib and Pegylated Interferon Alfa-2b Results in High Molecular Response Rates in Chronic Phase CML: Interim Results of the ALLG CML 11 Pinnacle StudyDavid T Yeung, On Behalf of the ALLG, Andrew Grigg et al.|Blood|2018Cited by 8
Combination of Nilotinib and Pegylated Interferon Alfa-2B Results in High Rates of MR4.5 at 24 Months - Primary Analysis of the ALLG CML 11 Pinnacle StudyDavid T Yeung, On Behalf of the ALLG, Naranie Shanmuganathan et al.|Blood|2019Cited by 7